PARP1 and cancer: While the focus of this review is on BRCA-mutant cancers, it is also important to note that BRCA wild-type (WT) and HR-proficient cancers have been shown to respond to PARPi as well, due to stabilization of PARP1 on DNA upon PARPi treatment, a process known as PARP trapping, forming replication obstacles (4).